NCT06986070 (SORT-COPD) is a Phase 1 clinical trial of Stem cells in Chronic Obstructive Lung Disease, sponsored by SMSbiotech.

Who is sponsoring NCT06986070?

NCT06986070 is sponsored by SMSbiotech.

What drugs are being tested in NCT06986070?

Interventions in NCT06986070: Stem cells.

What condition does NCT06986070 study?

NCT06986070 studies Chronic Obstructive Lung Disease.

Is NCT06986070 still recruiting?

NCT06986070 is currently recruiting now. Last updated 9 February 2026.

Last reviewed 2026-02-09 · How we verify

NCT06986070: SORT-COPD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase 1, First-in-Human, Clinical Trial to Evaluate the Safety of Small Mobile Stem Cells (SMS) Delivered Into the Lung as a Potential Organ Regeneration Therapy in Chronic Obstructive Pulmonary Disease (SORT-COPD Study

Recruiting now Phase 1 Last updated 9 February 2026

What this trial tests

Phase 1 trial testing Stem cells in Chronic Obstructive Lung Disease in 18 participants. Currently enrolling.

Timeline

13 June 2025

Primary endpoint
1 December 2026

1 December 2026

Quick facts

Lead sponsor	SMSbiotech
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	18
Start date	13 June 2025
Primary completion	1 December 2026
Estimated completion	1 December 2026
Sites	2 locations across Australia

Drugs / interventions tested

Stem cells — full drug profile →

Conditions studied

Chronic Obstructive Lung Disease — all drugs for Chronic Obstructive Lung Disease →

Sponsor

SMSbiotech

Who can join

Adults 39 to 69, any sex, with Chronic Obstructive Lung Disease. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Adverse events.
Time frame: Day 1, 2, 3, 4, 5, 8, 9, 21, 28, Month 3 and Month 6.
Treatment emergent adverse events and serious adverse events.
Dose limiting toxicity.
Time frame: Day 1, 2, 3, 4, 5, 8, 9, 21, 28, Month 3 and Month 6.
Any treatment emergent adverse event that ii treatment related and classified as severe or the event is classified as a serious adverse event.
Safety laboratory testing
Time frame: Screening, Day 2, 3, 5, 9, 21 and 28.
All laboratory parameters will be summarized using descriptive statistics for each cohort and overall, for all time points assessed, including change from baseline for all post-dose assessments. Selected laboratory test results will be graded in accordance with the NCI CTCAE criteria.

Sponsor's own description

This study is a phase 1, first-in-human, open-label, non-randomized, dose escalation safety study of 18 participants, between 39 and 69 years of age, with mild to moderate chronic obstructive pulmonary disease, treated with SORT-COPD (SMS cells). The primary objective of this study is to determine the safety of SORT-COPD (SMS cells) at three doses in people with chronic obstructive pulmonary disease.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Stem cells in organogenesis and regeneration.
Mim TJ, Ahmad I, Basher SR, Rahman MF, et al · · 2026 · cited 2× · PMID 41549301 · DOI 10.1186/s13287-025-04889-z

Verify or expand the search:

Other trials of Stem cells

Trials testing the same drug.

NCT06841328 — Fertility Enhancement Through Regenerative Treatment in Ovaries and Testes · recruiting
NCT04776538 — Safety and Efficacy of Mesenchymal Stem Cell for Radiation-induced Hyposalivation and Xerostomia in Previous Head and Ne · Phase 2 · unknown
NCT03308006 — Knee Osteoarthritis Treatment With Adipose-derived Stem Cells: Phase II Clinical Trial · Phase 2 · completed

Other recruiting trials for Chronic Obstructive Lung Disease

Currently open trials in the same condition.

NCT07460999 — Singing Training vs Usual Care 6-18 Months After Surgical Resection for Non-small Cell Lung Cancer (NSCLC) · NA · recruiting
NCT07015216 — Effects of Virtual Reality-Assisted Dual Task Training on Muscle Oxygenation in Patients With COPD · NA · recruiting
NCT06629675 — Make Every Step Count: Personalised Music Feedback to Walking for People Living With COPD · NA · recruiting
NCT06713512 — InvEstigating oeStrogen Signalling and the Effect upoN the exTracelluar Matrix In pAtients With Obstructive Lung Disease · recruiting
NCT05227547 — Mapping and Characterization of Alveolar Cells During Smoking and Chronic Obstructive Disease · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06986070 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by SMSbiotech
Last refreshed: 9 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06986070.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing